Flow-diverting stents for distal brain aneurysms

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational registry collects clinical and imaging data from adults aged 18–80 who receive flow-diverting stents for distal intracranial aneurysms. Eligible aneurysms include wide-neck saccular, fusiform, recurrent saccular, and dissecting aneurysms in distal branches of the Circle of Willis (for example MCA M1–M3, ACA A1–A3, PCA P1–P2). The study records procedural details, peri-procedural complications, and follow-up angiographic occlusion and clinical outcomes to characterize real-world safety and effectiveness. No experimental interventions are assigned and treatment follows local clinical practice while outcomes are analyzed.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 18 to 80 years, any gender，Subjects who have accepted treatment with flow-diverting for distal intracranial aneurysms
2. Diagnosed with an intracranial aneurysm by CTA, MRA, or DSA, with the following features: a wide neck (≥4mm), or a dome-to-neck ratio \<2, saccular, fusiform aneurysms, recurrent saccular aneurysms, and dissecting aneurysms. Locations include: the Circle of Willis and it's distal branches such as the middle cerebral artery (MCA) M1-M3 segments, anterior cerebral artery (ACA) A1-A3 segments, posterior cerebral artery (PCA) P1-P2 segments, etc. (intracranial aneurysms of the Circle of Willis and it's distal vessels).
3. Subject or guardian is able to understand the purpose of study, shows sufficient compliance with the study protocol and provides a signed informed consent form

Exclusion Criteria:

1. Conditions that are not appropriate for stent delivery and deployment judged by investigators (severe stenosis of parent artery, severe tortuosity of parent artery, stent failing to reach the lesion, stent in the target lesion of parent artery, etc.)
2. mRS score ≥3
3. Heart, lung, liver and renal failure or other severe diseases (intracranial tumor, systemic infection, disseminated intravascular coagulation, myocardial infarction within 12 months before enrollment, history of severe psychosis, severe stenosis or occlusion of cerebral feeding artery, etc.)
4. Platelet count \<60×10\^9/L, known platelet dysfunction, or international normalized ratio (INR) \>1.5
5. Major surgery within 30 days before enrollment，or planned to undergo surgery within 360 days after enrollment
6. Known allergies or contraindications to anesthetics, anticoagulants, and antiplatelet drugs
7. Pregnant or breastfeeding women
8. Subject has participated in other clinical trials within 1 month before signing informed consent
9. Other conditions judged by the investigators as unsuitable for enrollment

Where it's running

• First Affiliated Hospital of Zhejiang University
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: yuanyuan Shen
• Email: y.shen@zju.edu.cn
• Phone: 13958020971

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Progression and Management of Coronary Artery Aneurysms in Adults

  A group at Nanjing First Hospital is testing how coronary artery aneurysms change over time and how different treatment approaches affect outcomes in adults.

  Recruiting Nanjing First Hospital, Nanjing Medical University · Nanjing, Jiangsu · NCT07764081

• Evaluating outcomes in neurosurgery using standardized measures

  This study is trying to see how different factors affect the results of brain surgeries by collecting information from patients before and after their operations.

  Recruiting at 11 sites Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · Bergamo, BG and 26 other locations · NCT06724029

• Belumosudil vs. Ruxolitinib for hepatic cGVHD after HSCT

  This trial tests whether belumosudil or ruxolitinib works better for hepatic chronic GVHD after a stem cell transplant in people 12 and older.

  Recruiting First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang · NCT07794514

• Gastric protection after transplant: switch from PPI to teprenone to see effects on GVHD

  This trial tests whether switching from a proton pump inhibitor to teprenone after allogeneic HSCT changes the risk of acute graft-versus-host disease in patients with hematologic cancers.

  Recruiting First Affiliated Hospital of Zhejiang University · Hangzhou · NCT07791849

• Gut microbes and blood signals in sepsis-related liver and kidney injury

  This study tests whether gut microbes and blood markers differ in adults with sepsis who develop liver or kidney injury, compared with healthy volunteers.

  Recruiting at 6 sites First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang and 5 other locations · NCT07735182

• Eculizumab for high-risk TA-TMA in adult HSCT recipients

  This trial tests whether eculizumab can help adults with high-risk TA-TMA after allogeneic stem cell transplantation.

  Recruiting at 8 sites Phase 2 First Affiliated Hospital of Zhejiang University · Changsha, Hunan and 7 other locations · NCT07707687

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.